It is very uncertain whether single‐dose changes re‐infection compared with short‐course (3‐7 days) antibiotics (very low certainty).
Epoetin alfa every four weeks showed no clear difference in adverse events: RBC transfusions compared with with every two weeks (low certainty).
Epoetin alfa every four weeks showed no clear difference in adverse events: hypertension compared with with every two weeks (moderate certainty).
Epoetin alfa every four weeks showed no clear difference in adverse events: arteriovenous complications compared with with every two weeks (low certainty).
Epoetin theta showed no clear difference in deaths compared with epoetin beta (low certainty).
Epoetin theta showed no clear difference in adverse events: hypertension compared with epoetin beta (moderate certainty).
Epoetin theta showed no clear difference in adverse events: RBC transfusions compared with epoetin beta (low certainty).
Epoetin theta showed no clear difference in adverse events: discontinuation of therapy compared with epoetin beta (low certainty).
Epoetin alpha every 2 weeks may leads to lower number reaching target Hb compared with to weekly (low certainty).
Epoetin alpha every 2 weeks showed no clear difference in number of deaths compared with to weekly (low certainty).
Epoetin alpha every 2 weeks showed no clear difference in adverse events: RBC transfusions compared with to weekly (low certainty).
Epoetin alpha every 2 weeks showed no clear difference in adverse events: hypertension compared with to weekly (moderate certainty).
Epoetin alpha every 2 weeks showed no clear difference in adverse events: thrombovascular events compared with to weekly (low certainty).
It is very uncertain whether epoetin alfa every four weeks changes number reaching target Hb compared with with every two weeks (very low certainty).
Epoetin alfa every four weeks showed no clear difference in number of deaths compared with with every two weeks (low certainty).